UBS O'Connor’s Celgene Corp CELG Stock Holding History

UBS O'Connor’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,491,255	Closed	-$545M	–	411
2019 Q3	$545M	Buy	5,491,255 +2,868,092	+109%	+$273M	15.17%	1
2019 Q2	$242M	Buy	2,623,163 +1,221,569	+87%	+$116M	4.7%	6
2019 Q1	$132M	Buy	+1,401,594	New	+$123M	3.69%	5
2013 Q3	–	Sell	-86,000	Closed	-$5.03M	–	665
2013 Q2	$5.03M	Buy	+86,000	New	+$5.18M	0.09%	237

Other funds holding CELG

HCM

Howard Capital Management Roswell, Georgia $8.4B AUM 51.89% 1-Year Est. Return

PCMC

Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return

UBS O'Connor's CELG Position: Q4 2019 in Review

UBS O'Connor sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 5,491,255 shares — an estimated $545M sold.

UBS O'Connor first reported a position in CELG in Q2 2013 and held it in 4 quarters. The position peaked at $545M in Q3 2019. 3 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

UBS O'Connor reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
UBS O'Connor sold 5,491,255 Celgene Corp shares in Q4 2019, an estimated $545M.
UBS O'Connor first reported a position in Celgene Corp in Q2 2013 and held it in 4 quarters.
UBS O'Connor's Celgene Corp position peaked at $545M in Q3 2019.
3 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on UBS O'Connor's 13F filing for Q4 2019, filed 14 Feb 2020.